Key Insights

Highlights

Treatment Research

2 treatments under study, led by Rifaximin 550 Milligram Oral Tablet Xifaxan

Research Leaders

8 sponsors active, led by Erasmus Medical Center

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 4 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT04073290Phase 4Recruiting

Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose

Showing all 1 trials

Research Network

Common Treatments

  • Rifaximin 550 Milligram Oral Tablet Xifaxan1
  • Lactulose 667 Milligrammilliliter Oral Solution1

Active Sponsors

  • Erasmus Medical Center1
  • Norgine1
  • University Medical Center Groningen1
  • Universitaire Ziekenhuizen KU Leuven1
  • Radboud University Medical Center1

Top Investigators

Related Conditions

  • Pathological Processes1
  • Liver Diseases1
  • Cirrhosis Liver1
  • Hepatic Encephalopathy1
  • Portal Hypertension1

Activity Timeline